2023-04-18 02:04:00
A vaccination against skin cancer from the US company Moderna shows promising results in a clinical study with a small group of patients. The risk of a new illness was reduced by 40 percent. 157 patients with a high risk of cancer recurrence were included in the scientific study. Of them, 50 received the previous standard therapy with the so-called checkpoint inhibitor pembrolizumab. Such immunotherapy is intended to be the body’s own
1681784866
#mRNA #vaccination #recurrence #skin #cancer
Related posts:
Russian Tank Ambush: Ukrainian Army Destroys Hidden Enemy Tank in Woods
Protests against Samsung in Pakistan for blaspheming the Prophet
2023 Eco Forum Global Guiyang: Advancing Green and Low-carbon Development in China
Brazil Borrows Emperor Pedro I 'Heart' from Portugal to Celebrate 200 Years of Independence
Perez takes pole position in Saudi Arabia - defect at Verstappen - Formula 1
AC/DC in Vienna: This is how much the tickets cost
"Sudan Unrest: Rapid Support Forces Claim Sweeping Victories in Clashes with Army"
Affordable Natural Christmas Tree Program: Cut Your Own Tree in Protected Forests for $5